The optimal timing of the Fontan staging for a univentricular heart and its impact on growth remains debateable. In a Fontan cohort, the influence of staged interventions and patient factors on somatic development was explored.
INTRODUCTION
Children with a functionally univentricular heart (UVH) need several surgical procedures that ultimately result in a Fontan circulation. It is commonly accepted that this surgical pathway is best performed as a sequence of staged operations during infancy and childhood, to benefit mortality and morbidity by the gradual reduction of the volume overload and cyanosis [1, 2] . The improvement in neonatal management, operative techniques and postoperative care has further reduced early mortality and morbidity in such a way that emphasis in the management of the Fontan patient nowadays has shifted from pure survival to strategies enhancing their quality of life and reducing the adverse long-term effects of the Fontan circulation.
A failure to thrive in a growing child is determined as physical growth that is significantly less than that of their peers. An acute failure to thrive is a well-known feature in infants with cardiac defects with large left-to-right shunts, and is usually characterized by a weight score of <2 SD (standard deviations) below normal for age, or a drop on the weight curve of 1-2 SD over 3-6 months. A prompt correction of the heart problem usually results in a swift catch-up growth in the months following the surgical repair [3] . A chronic failure to thrive usually implies height retardation, and may be defined as length for age of <2 SD, or slowing down of the curve by 0.5-1 SD (under 4 years of age) or 0.25 SD (over 4 years of age) [4] . Follow-up studies on the somatic growth in children with a univentricular physiology are scarce and show inconsistent results, but currently suggest a less favourable somatic development during early childhood and persisting into adolescence [5] [6] [7] . Overweight is uncommon in Fontan patients compared with children with other congenital heart diseases [8] . It remains unclear which factor is mainly affecting body growth: the substrate of the single ventricle physiology by itself, a combination of congestive heart failure and cyanosis, the timing of the obligatory surgical steps from the first neonatal surgery to the total cavopulmonary connection (TCPC) with its inherent fluctuations in the volume load and the degree of cyanosis, an occurrence of residual or new cyanosis after the TCPC, or the hazardous long-term performance of the single ventricle.
In the present study, we aim to explore the trends in body growth in relation to consecutive surgical and interventional procedures, and to define patient and procedural factors that may interfere with somatic development.
MATERIALS AND METHODS

Patient population
In a retrospectively designed study, 64 consecutive patients with a functionally single ventricle, who embarked on the Fontan pathway and ultimately underwent a TCPC at the Cardiac Centre, University Hospital Ghent, Belgium from 1992 to 2009, were reviewed. Patients with a low birth weight and prematurity were not excluded.
The demographic data and the primary diagnosis are listed in Table 1 .
The institutional Ethical Committee approved the study and waived the need for patient consent, as only routine patient data noted at the time of the interventions and during outpatient clinic visits were utilized.
Methods
The serial weight, height and oxygen saturation from each patient at birth, and at each hospital admission and outpatient clinic visit were collected from the patient files, and anthropometric data were converted to z-scores for a comparative analysis. Z-scores were used rather than the more commonly used percentiles, as they express more accurately values at the extreme end of the spectrum. A z-score of 0 is equivalent to a percentile of 50%, z-scores of −2, −1.3, +1.3 and +2 are equivalent to percentiles of 3, 10, 90 and 97%, respectively. A total of 765 time points were scored, for an average of 12 per patient. From the surgical files details of procedures, oxygen saturation and medical therapy were collected. Neonatal surgery or the first surgery was categorized as a shunt procedure or pulmonary artery banding when examining the correlation of the type of neonatal surgery to other factors. Data on the bidirectional cavopulmonary anastomosis (BCPA), the type of the TCPC, the presence of a fenestration and associated procedures were registered. All data on interim interventional procedures were listed. 
Statistical analysis
RESULTS
Patient and interventional data
The 64 patients who underwent the Fontan completion have been followed up from birth to the last outpatient clinic visit for a mean of 12.5 ± 6.1 years.
A first surgical procedure was performed at a median age of 20 days (range 0-1456 days) in 57 patients (89%). At a median age of 11.9 months (range 5.5-76 months) 56 patients (87%) underwent a BCPA stage, which was accompanied by a concomitant surgical procedure in 25 patients. The TCPC was performed at a median age of 3.2 years (range 2.2-18.3 years). Eight patients, operated on before 1995, had no BCPA stage and went directly from a first surgical procedure to the TCPC after a median interval of 5.2 years (range 3.5-12.2 years). The median interval between the BCPA and the TCPC was 2.3 years (range 0.6-14.4 years) in the remaining 56 patients.
In 30 patients, 47 additional interim surgical or catheter interventions were performed: nine before the BCPA, and 11 before and 27 after the TCPC. The information about the number and type of procedures is listed in Table 2 .
Three patients (4.7%) died in hospital after the TCPC procedure; no late deaths occurred. The surviving 61 patients had a mean follow-up of 7.9 ± 4.9 years after the TCPC. Two patients were lost to follow-up 2 years after the TCPC, and so the patient follow-up was 92% complete. The ventricular dominance was left in 34 patients, right in 22 patients and undifferentiated in eight.
Evolution of biometry
The mean birth weight and height of the patients was 3.1 ± 0.6 kg and 49.2 ± 2.8 cm with a mean z-value of −0.3 ± 1.2 and 0 ± 1 for weight and height, respectively. At the time of the first surgery, the mean weight and height were mainly unchanged with 3.8 ± 1.6 kg and 53 ± 7 cm representing a mean z-value, respectively, which significantly decreased to −1.3 ± 1.9 for weight and −0.9 ± 1.7 for height (P < 0.0001 compared with birth). The mean weight and height at the BCPA stage of 8.5 ± 2.6 kg and 75 ± 12 cm, respectively, represented a significant further decline of the z-value to −2.1 ± 1.2 for weight and −1.6 ± 1.3 for height (P < 0.0001 compared with the first surgery). After the BCPA both weight and height recovered significantly, to reach a mean weight 16.3 ± 7.6 kg (z-score of −1.2 ± 1.3) and a mean height of 103 ± 18 cm (z-score of −0.7 ± 1.4) at the time of the TCPC (P < 0.0001 compared with the BCPA). Although the weight continued to recover slightly in some patients, reaching a mean z-value of −0.8 ± 1.6 (mean weight 37.5 ± 18 kg) at last the follow-up (FU), this change in z-value was not significantly different in comparison with the weight at the TCPC stage. The proportional height stagnated after the TCPC, as was clearly delineated by the mean z-value of −0.7 ± 1.3 at last the FU (mean height of 142 ± 24 cm). The changes in z-scores between the different surgical stages are depicted in Fig. 1 . Multivariate linear regression models of the time-related evolution of weight and length were not affected by gender, prematurity or the ventricle type.
When expressed as percentiles, the results show that at birth the patients are evenly distributed around the fiftieth percentile (P50): 67% are <P50 for weight and 55% <P50 for height. At the first surgical stage, already 81% are <P50 for weight, and 69% for height. At the BCPA operation nearly all patients are <P50. By the time of the TCPC, 89 and 77% are <P50 for weight and height, respectively. After the Fontan completion, 77% of patients demonstrated an increase in weight, but only half of the patients showed some catch-up growth in length, while the overall group remained small for age (78% <P50) at the last outpatient clinic. At the last FU still 10 and 17% of patients were <P3 for weight and height, respectively. Evolution of mean z-scores for weight and height at different time points during Fontan staging. P < 0.001 is significant between stages. Z-scores at birth (zbirth), at first surgery (z1st), at BCPA (zBCPA), at TCPC (zTCPC) and at last follow-up (zlastFU). 
CONGENITAL
Factors influencing body growth
The influence of several anatomical, physiologic, medical and surgical factors on body growth is listed in Table 3 . At the time of the BCPA, the z-values for both the weight and the length reached a nadir. In the univariate analysis, only the need for previous palliative surgery showed a tendency to influence body growth adversely (z-weight = −2.2 ± 1.2 versus −1.4 ± 1.0; P = 0.09 and z-length = −1.7 ± 1.3 versus −0.7 ± 1.0; P = 0.05), independently of the type of palliation.
The age at the BCPA did not account for a significant impact on the z-scores for the weight and the height at the time the BCPA was performed, but only two patients in the group were <6 months of age at the BCPA.
Multivariate linear regression analysis revealed that a younger age at the BCPA was predictive for a higher weight at the time of the TCPC (standardized β = −0.30; P = 0.04). The interval time between the BCPA and the TCPC was, however, not significant (P = 0.44). This finding was more relevant for the weight than for the length (Table 3) .
The weight at the last follow-up was independently affected by the use of angiotensin converting enzyme inhibitors (ACE-I) (standardized β = −0.34; P = 0.009), while the ventricle type did not achieve significance (P = 0.07). Otherwise, length at latest control indicated right ventricular morphology (standardized β = 0.31; P = 0.02) and intake of ACE-I (standardized β = −0.35; P = 0.006) as independent predictive factors.
Patients with a dominant right (RV) or left ventricle (LV) showed an identical pattern of z-score changes over the different time points, but the mean birth weight of neonates with a dominant RV was commonly higher (z-score for weight: 0.3 ± 1.0 and −0.5 ± 1.2 for the RV and LV, respectively; P = 0.02). In accordance, children with RV dominance were still taller at the last follow-up (z-weight LV = −1.0 ± 1.3 and z-weight RV = 0.3 ± 1.2; P = 0.04).
During follow-up, 36% of the patients (31% of patients with a dominant LV and 45% with a dominant RV) were treated with the ACE-I lisinopril, mainly for the echocardiographic features of diminished ventricular function or atrioventricular valve incompetence in a preclinical stage. Univariate and multivariate analyses demonstrated a significant effect of the use of ACE-I on the z-scores for weight (z-value for the use of ACE-I = −1.5 ± 2.1 versus the non-use of ACE-I = −0.4 ± 1.1; P = 0.014) and height (z-value for the use of ACE-I = −1.3 ± 1.5 versus the non-use of ACE-I = −0.4 ± 1.1; P = 0.013) at the last FU. Indirectly, this suggests a negative influence of latent cardiac failure on the somatic growth in children with a UVH after a Fontan completion (Fig. 2) .
In contrast to the occasional catch-up growth, we encounter after the closure of important collaterals or a large fenestration in a single Fontan patient, oxygen saturation had no significant impact on the somatic growth at any stage, neither did the presence of a fenestration or the need for interventional procedures aimed at reducing cyanosis after the TCPC.
DISCUSSION
Trends in somatic growth over the Fontan course and timing of the stages
In this study, the UVH patients were slightly underweight at birth with a normal birth length, which further declined towards the first palliation. A dramatic decrease in the somatic scores was seen before the BCPA, when the z-scores for weight and height reached their nadir. In a comparable group of patients, Vogt et al. [7] found a same decline before the BCPA, however, the lower z-values were less pronounced than in our study (weight −1.6 and height −0.6), which may be explained by the younger median age at the BCPA of 8.4 months. They also noticed a significant negative influence of a first surgical palliation preceding the BCPA on the downward evolution in somatic growth. In a retrospective study on 50 infants after a Norwood procedure, Kelleher et al. [9] described a weight-for-age decline from −0.4 before the Norwood procedure to −1.4 at discharge, and a further decrease to −2.0 before the BCPA. Less calorie intake, frequent readmissions and a higher saturation at discharge had a significant impact on growth retardation. A prospective study on 61 infants with a UVH undergoing a neonatal procedure found a decrease in the z-score for weight with 1.5 units between intervention and discharge, advancing atrioventricular valve regurgitation and a complicated postoperative course as risk factors for poor weight gain [10] . Despite more than half of the patients in this study having feed device support, the babies on oral feeds showed more favourable growth patterns. It was speculated that the methods or the timing of feeding augmentation were insufficient for adequate weight gain. However, through the strict implementation of home monitoring and a standard feeding plan with gastrostomy in 33% of their Norwood patients, Hehir [11] obtained a near normal weight gain in the majority of patients, with superb outcome results after the BCPA, performed at an early mean age of 3.9 months but in patients weighing 5.6 kg on average. In our study, the mean age of 10.8 months at the BCPA reflects the idea that most children were regarded as having a 'well balanced' circulation, and so there was often no hurry to perform the BCPA procedure earlier. Historically, no additional nutritional support was offered to these patients either. The serious decline in the growth parameters before the BCPA we found in our study, in accordance to others, and the encouraging results from feeding programmes may favour performing the BCPA systematically at a younger age. However, taking into consideration that younger age combined with a lower weight z-score is related to a longer hospital stay after the BCPA [12] , preoperative optimization of the nutritional status might be helpful. Recent evidence warned against lowering the age at the BCPA to below 3 months, as this was independently associated with a decreased progression to Fontan completion [13] . In our series, only a small number of patients underwent the BCPA before the age of 6 months, and so further studies on the BCPA performed at a few months of age have to be done before drawing firm conclusions on the benefit of advancing the age at the BCPA on somatic growth. Similar to previous studies [5, 7, 14] , we found a significant catch-up growth after the BCPA in the majority of patients, with an increased weight gain when the BCPA was performed earlier, probably due to the important ventricular unloading through the BCPA. This favourable trend in growth continues at a slower pace after the TCPC, resulting in an ongoing progress in the z-score for weight at the last FU, albeit less pronounced in patients undergoing the TCPC beyond the fifth year of age. In a historical cohort of 90 Fontan patients, of which only 25% underwent completion through staging, Ono et al. described improved somatic development after an early Fontan completion. A prior BCPA provided better weight gain before the Fontan operation in their series [15] .
In contrast to the data on weight, we found no more significant change in the height for age after the Fontan completion into adolescence, a finding we share with Cohen et al. [6] and Vogt et al. [7] in patient groups comparable for age and the duration of follow-up. In studies exploring the growth of patients with an extracardiac Fontan conduit [16, 17] or lateral tunnel [18] , the weight gain was more pronounced than the increase in body length. A Fontan completion over the age of 4 years induced less accelerated growth, a trend we noted in patients older than 5 years at the time of TCPC. A mechanism of chronic hypoxia that impairs bone development at a crucial early age with an ongoing impact even after the Fontan completion has been suggested to explain the deficient growth with respect to height [7] . On the contrary, in a retrospective study, Hasan et al. compared Fontan patients with a Mustard population, both groups starting with a comparable weight and height retardation before operation. Catch-up growth in weight occurred in both groups, but in the Mustard group height also normalized, whereas in the Fontan group height remained abnormally low, suggesting that other mechanisms were involved in chronic failure to thrive [19] .
The disproportional gain in weight compared with height that we and others observed in growing Fontan children may also be the consequence of reduced physical activity and resulting adiposity, which may predispose one to ventricular hypertrophy and reduced cardiac performance. A cross-sectional review of 12-year olds with congenital and acquired heart disease in the Philadelphia and Boston region showed a prevalence of overweight in Fontan children of 15.9%, which was, however, significantly lower than the 25% obese children in the other categories [8] . With only two patients reaching a z-score for weight >1 at the last FU, overweight in our series is not an issue.
Factors influencing somatic growth
Regarding ventricular dominance, a UVH with a dominant RV proved to be beneficial for somatic growth at the last follow-up, an unexpected finding not sustained by the literature. Apart from the fact that babies born with a dominant right ventricular morphology were larger at birth and at the first surgery, the growth patterns over the different time points ran identical in Figure 2 : Influence of the use of ACE-inhibitors after TCPC on somatic scores at last follow-up. P < 0.001 is significant between stages.
both hypoplastic RV and LV groups. As more patients with a single RV received ACE-I at the latest contact, it is possible that with an extended FU time the long-term performance of the different single ventricle types will change this trend.
An interesting finding from our study was the significant negative correlation between the z-scores for weight and height at the last FU and the use of ACE-I treatment. The negative action of long-term ACE-I use on somatic development is probably a surrogate for preclinical cardiac failure, as lisinopril was mainly given for echocardiographic features of diminished ventricular performance and atrioventricular valve incompetence. Day et al. [5] demonstrated the association of atrioventricular valve regurgitation and impaired growth up to 4 years after Fontan completion. Cohen et al. [20] found in a multicentre database of Fontan patients an association between shorter stature in adolescents and atrioventricular valve regurgitation, as that between a poorer functional health status and developmental problems. In the pre-Fontan period, we could not find any detrimental effect of the use of ACE-I on somatic growth, in contrast to Vogt et al. [7] who demonstrated a significant influence of cardiac medications on the weight for age before the TCPC. The administration of lisinopril in the postoperative phase after the BCPA (41% of patients) was, however, sometimes arbitrary and often temporary, as only 28% of the patients admitted for the TCPC were still on lisinopril; or the interval between the BCPA and the TCPC was too short to show an important drug effect.
The majority of our patients after the TCPC had an oxygen saturation of >90%, even with a residual fenestration. In comparison with patients with lower oxygen saturation during more than 1 year, the z-scores for weight and height at the last FU were similar. According to Vogt et al. [7] , one could not find any significant influence of closure procedures of venous collaterals or fenestrations on the cohort, probably because very few patients had long periods of significant cyanosis, as large venous collaterals were actively sought out and coiled. Goff et al. [21] described improved somatic growth after fenestration closure shortly after the TCPC, but the difference could still be attributed to normal catch-up growth. These findings support the suggestion that occlusion of a small fenestration is not necessary for growth, as mild desaturation is well tolerated and allows catch-up growth [15] .
LIMITATIONS OF THE STUDY
Despite the limitations due to the retrospective design, patient data on somatic scores are complete for 94%, as the measurements of weight, height and saturation were standard at each hospital visit. As the follow-up after the TCPC was almost complete, and patients were evenly distributed across the study period, we consider the data as reliable.
The z-scores for the weight and height we used are based on the reference data for the Belgian population, which may not be fully representative for patients with a different ethnic background.
This study covers a patient cohort, including some strategy changes over time. The timing of different Fontan stages underwent an evolution during the course of the study: nowadays the completion of Fontan circulation in our centre is routinely done through staging and finalized before the age of 4 years; the BCPA is performed more consistently at a younger age independent of the anatomy.
CONCLUSION
This longitudinal observational study demonstrates that body growth during childhood and into adolescence is severely impaired in patients with the UVH treated with a Fontan circulation.
A close interstage follow-up between the first surgery and the BCPA must be targeted at optimal nutritional support to counter the important growth retardation occurring before the BCPA. The better catch-up growth at the TCPC when the BCPA is performed earlier in life, sustains the current trend to perform the BCPA at a younger age. Heart failure treatment after the Fontan completion has a significantly inverse relationship with late somatic development.
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